Differential survival of AML subpopulations in NOD/SCID mice

Experimental Hematology

Volumn 39, Issue 2, 2011, Pages

  Schubert, Mario ^a   Herbert, Nicolás ^a   Taubert, Isabel ^a   Ran, Dan ^a   Singh, Rahul ^a   Eckstein, Volker ^a   Vitacolonna, Mario ^a   Ho, Anthony D ^a   Zöller, Margot ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL EXPANSION; CELL SURVIVAL; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EX VIVO STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MONONUCLEAR CELL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE;

MUS;

EID: 78751496866     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2010.10.010     Document Type: Article

References (89)

1. Bullinger L., Armstrong S.A. HELP for AML: methylation profiling opens new avenues. Cancer Cell 2010, 17:1-3.
2. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005, 5:311-321.
3. Krause A., Luciana M., Krause F., Rego E.M. Targeting the acute myeloid leukemia stem cells. Anticancer Agents Med Chem 2010, 10:104-110.
4. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
5. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
6. Schlenk R.F., Döhner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009, 16:98-104.
7. Ishikawa F., Yoshida S., Saito Y., et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007, 25:1315-3121.
8. Estey E., Döhner H. Acute myeloid leukaemia. Lancet 2006, 368:1894-1907.
9. Pearce D.J., Taussig D., Zibara K., et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006, 107:1166-1173.
10. Wieser R., Scheideler M., Hackl H., et al. microRNAs in acute myeloid leukemia: expression patterns, correlations with genetic and clinical parameters, and prognostic significance. Genes Chrom Cancer 2010, 49:193-203.
11. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
12. Taussig D.C., Pearce D.J., Simpson C., et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005, 106:4086-4092.
13. Cheung A.M., Wan T.S., Leung J.C., et al. Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia 2007, 21:1423-1430.
14. Pearce D.J., Taussig D., Simpson C., et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005, 23:752-760.
15. Ran D., Schubert M., Pietsch L., et al. Aldehyde dehydrogenase activity among primary leukemia cells is associated with stem cell features and correlates with adverse clinical outcomes. Exp Hematol 2009, 37:1423-1434.
16. Moreb J.S. Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 2008, 3:237-246.
17. Christ O., Lucke K., Imren S., et al. Improved purification of hematopoietic stem cells based on their elevated aldehyde dehydrogenase activity. Haematologica 2007, 92:1165-1172.
18. Muramoto G.G., Russell J.L., Safi R., et al. Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. Stem Cells 2010, 28:523-534.
19. Pierre-Louis O., Clay D., de la Grange P.B., et al. Dual SP/ALDH functionalities refine the human hematopoietic Lin-CD34+CD38- stem/progenitor cell compartment. Stem Cells 2009, 27:2552-2562.
20. Figueroa M.E., Wouters B.J., Skrabanek L., et al. Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 2009, 113:2795-2804.
21. Chao M.P., Seita J., Weissman I.L. Establishment of a normal hematopoietic and leukemia stem cell hierarchy. Cold Spring Harb Symp Quant Biol 2008, 73:439-449.
22. Kirouac D.C., Madlambayan G.J., Yu M., Sykes E.A., Ito C., Zandstra P.W. Cell-cell interaction networks regulate blood stem and progenitor cell fate. Mol Syst Biol 2009, 5:293.
23. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114:1150-1157.
24. Rizo A., Olthof S., Han L., Vellenga E., de Haan G., Schuringa J.J. Repression of BMI1 in normal and leukemic human CD34(+) cells impairs self-renewal and induces apoptosis. Blood 2009, 114:1498-1505.
25. Vitacolonna M., Schubert M., Herbert N., et al. Improved T and B cell recovery by the transfer of slowly dividing human hematopoietic stem cells. Leuk Res 2009, 34:622-630.
26. Foster L.J., Zeemann P.A., Li C., et al. Differential expression profiling of membrane proteins by quantitative proteomics in a human mesenchymal stem cell line undergoing osteoblast differentiation. Stem Cells 2005, 23:1367-1377.
27. Wagner W., Wein F., Roderburg C., et al. Adhesion of hematopoietic progenitor cells to human mesenchymal stem cells as a model for cell-cell interaction. Exp Hematol 2007, 35:314-325.
28. Shimizu I., Fudaba Y., Shimizu A., Yang Y.G., Sykes M. Comparison of human T cell repertoire generated in xenogeneic porcine and human thymus grafts. Transplant 2008, 86:601-610.
29. Shpitz B., Chambers C.A., Singhal A.B., et al. High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. J Immunol Methods 1994, 169:1-15.
30. Kuhn N.Z., Tuan R.S. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. J Cell Physiol 2010, 222:268-277.
31. Tárnok A., Ulrich H., Bocsi J. Phenotypes of stem cells from diverse origin. Cytometry A 2010, 77:6-10.
32. Walenda T., Bork S., Horn P., et al. Co-culture with mesenchymal stromal cells increases proliferation and maintenance of hematopoietic progenitor cells. J Cell Mol Med 2010, 14:337-350.
33. Fernandez H.F., Rowe J.M. Induction therapy in acute myeloid leukemia: intensifying and targeting the approach. Curr Opin Hematol 2010, 17:79-84.
34. Robak T., Wierzbowska A. Current and emerging therapies for acute myeloid leukemia. Clin Ther 2009, 31(Pt 2):2349-2370.
35. Storb R. Reduced-intensity conditioning transplantation in myeloid malignancies. Curr Opin Oncol 2009, 21(suppl 1):S3-S5.
36. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009, 27:6041-6051.
37. Estey E. New drugs in acute myeloid leukemia. Semin Oncol 2008, 35:439-448.
38. Saito Y., Uchida N., Tanaka S., et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010, 28:275-280.
39. Buzzai M., Licht J.D. New molecular concepts and targets in acute myeloid leukemia. Curr Opin Hematol 2008, 15:82-87.
40. Ailles L.E., Gerhard B., Kawagoe H., Hogge D.E. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999, 94:1761-1772.
41. Feuring-Buske M., Gerhard B., Cashman J., Humphries R.K., Eaves C.J., Hogge D.E. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 2003, 17:760-763.
42. Fukuchi Y., Miyakawa Y., Kizaki M., et al. Human acute myeloblastic leukemia-ascites model using the human GM-CSF- and IL-3-releasing transgenic SCID mice. Ann Hematol 1999, 78:223-231.
43. Tavor S., Petit I., Porozov S., et al. Motility, proliferation, and egress to the circulation of human AML cells are elastase dependent in NOD/SCID chimeric mice. Blood 2005, 106:2120-2127.
44. Wilson A., Oser G.M., Jaworski M., et al. Dormant and self-renewing hematopoietic stem cells and their niches. Ann N Y Acad Sci 2007, 1106:64-75.
45. Blair A., Hogge D.E., Sutherland H.J. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34(+)/CD71(-/HLA-DR- Blood 1998, 92:4325-4335.
46. Terpstra W., Prins A., Ploemacher R.E., et al. Long-term leukemia-initiating capacity of a CD34-subpopulation of acute myeloid leukemia. Blood 1996, 87:2187-2194.
47. Oostendorp R.A., Audet J., Miller C., Eaves C.J. Cell division tracking and expansion of hematopoietic long-term repopulating cells. Leukemia 1999, 13:499-501.
48. Young J.C., Varma A., DiGiusto D., Backer M.P. Retention of quiescent hematopoietic cells with high proliferative potential during ex vivo stem cell culture. Blood 1996, 87:545-556.
49. Bacher U., Kohlmann A., Haferlach C., Haferlach T. Gene expression profiling in acute myeloid leukaemia (AML). Best Pract Res Clin Haematol 2009, 22:169-180.
50. Brandts C.H., Berdel W.E., Serve H. Oncogenic signaling in acute myeloid leukemia. Curr Drug Targets 2007, 8:237-246.
51. Masson K., Rönnstrand L. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 2009, 21:1717-1726.
52. Small D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008, 45(suppl 2):S17-S21.
53. Jin L., Lee E.M., Ramshaw H.S., Busfield S.J., et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 2009, 5:31-42.
54. Moshaver B., van Rhenen A., Kelder A., et al. Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008, 26:3059-3067.
55. Powell J.A., Thomas D., Barry E.F., et al. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood 2009, 114:4859-4870.
56. Stein C., Kellner C., Kügler M., et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 2010, 148:879-889.
57. Feller N., van der Pol M.A., Waaijman T., et al. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients. Clin Cancer Res 2005, 11:4793-4801.
58. Ferrandina G., Petrillo M., Bonanno G., Scambia G. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009, 13:823-837.
59. Marhaba R., Klingbeil P., Nuebel T., Nazarenko I., Buechler M.W., Zöller M. CD44 and EpCAM: cancer-initiating cell markers. Curr Mol Med 2008, 8:784-804.
60. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
61. Watt S.M., Forde S.P. The central role of the chemokine receptor, CXCR4, in haemopoietic stem cell transplantation: will CXCR4 antagonists contribute to the treatment of blood disorders?. Vox Sang 2008, 94:18-32.
62. Barrena S., Almeida J., Yunta M., et al. Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 2005, 19:1376-1383.
63. Dunn C.D., Sulis M.L., Ferrando A.A., Greenwald I. A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells. Proc Natl Acad Sci U S A 2010, 107:5907-5912.
64. Hemler M.E. Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 2005, 6:801-811.
65. Levy S., Shoham T. Protein-protein interactions in the tetraspanin web. Physiology (Bethesda) 2005, 20:218-224.
66. Bonig H., Wundes A., Chang K.H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008, 111:3439-3441.
67. Christ O., Kronenwett R., Haas R., Zöller M. Combining G-CSF with a blockade of adhesion strongly improves the reconstitutive capacity of mobilized hematopoietic progenitor cells. Exp Hematol 2001, 29:380-390.
68. Qian H., Tryggvason K., Jacobsen S.E., Ekblom M. Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood 2006, 107:3503-3510.
69. Qin G., Ii M., Silver M., et al. Functional disruption of alpha4 integrin mobilizes bone marrow-derived endothelial progenitors and augments ischemic neovascularization. J Exp Med 2006, 203:153-163.
70. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
71. Neu S., Geiselhart A., Sproll M., et al. Expression of CD44 isoforms by highly enriched CD34-positive cells in cord blood, bone marrow and leukaphereses. Bone Marrow Transplant 1997, 20:593-598.
72. Pilarski L.M., Pruski E., Wizniak J., et al. Potential role for hyaluronan and the hyaluronan receptor RHAMM in mobilization and trafficking of hematopoietic progenitor cells. Blood 1999, 93:2918-2927.
73. Smadja-Joffe F., Legras S., Girard N., et al. CD44 and hyaluronan binding by human myeloid cells. Leuk Lymphoma 1996, 21:407-420.
74. Chan J.Y., Watt S.M. Adhesion receptors on haematopoietic progenitor cells. Br J Haematol 2001, 112:541-557.
75. Deguchi T., Komada Y. Homing-associated cell adhesion molecule (H-CAM/CD44) on human CD34+ hematopoietic progenitor cells. Leuk Lymphoma 2000, 40:25-37.
76. Woodward W.A., Sulman E.P. Cancer stem cells: markers or biomarkers?. Cancer Metastasis Rev 2008, 27:459-470.
77. Gadhoum Z., Leibovitch M.P., Qi J., et al. CD44: a new means to inhibit acute myeloid leukemia cell proliferation via p27Kip1. Blood 2004, 103:1059-1068.
78. Krause D.S., Lazarides K., von Andrian U.H., Van Etten R.A. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006, 12:1175-1180.
79. Zada A.A., Singh S.M., Reddy V.A., et al. Downregulation of c-Jun expression and cell cycle regulatory molecules in acute myeloid leukemia cells upon CD44 ligation. Oncogene 2003, 22:2296-2308.
80. Zou G.M. Cancer stem cells in leukemia, recent advances. J Cell Physiol 2007, 213:440-444.
81. Funayama K., Shimane M., Nomura H., Asano S. An evidence for adhesion-mediated acquisition of acute myeloid leukemic stem cell-like immaturities. Biochem Biophys Res Commun 2010, 392:271-276.
82. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006, 12:1167-1174.
83. Onoda M., Nakaseko C., Yokota A., Saito Y. Ligation of CD44 with low-molecular-weight hyaluronan and a monoclonal antibody leads to inhibition of drug-induced apoptosis in a human myeloid cell line. Hematology 2009, 14:213-219.
84. Tu L.C., Foltz G., Lin E., Hood L., Tian Q. Targeting stem cells-clinical implications for cancer therapy. Curr Stem Cell Res Ther 2009, 4:147-153.
85. Marhaba R., Bourouba M., Zöller M. CD44v7 interferes with activation-induced cell death by upregulation of anti-apoptotic gene expression. J Leukoc Biol 2003, 74:135-148.
86. Wittig B.M., Johansson B., Zöller M., Schwärzler C., Günthert U. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7). J Exp Med 2000, 191:2053-2064.
87. Liu J., Jiang G. CD44 and hematologic malignancies. Cell Mol Immunol 2006, 3:359-365.
88. Bendall L.J., Bradstock K.F., Gottlieb D.J. Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia 2000, 14:1239-1246.
89. Christ O., Günthert U., Haas R., Zöller M. Importance of CD44v7 isoforms for homing and seeding of hematopoietic progenitor cells. J Leukoc Biol 2001, 69:343-352.